DK3447149T3 - Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer - Google Patents

Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer Download PDF

Info

Publication number
DK3447149T3
DK3447149T3 DK18192671.8T DK18192671T DK3447149T3 DK 3447149 T3 DK3447149 T3 DK 3447149T3 DK 18192671 T DK18192671 T DK 18192671T DK 3447149 T3 DK3447149 T3 DK 3447149T3
Authority
DK
Denmark
Prior art keywords
cancer
cns
goal
diseases
prevention
Prior art date
Application number
DK18192671.8T
Other languages
English (en)
Inventor
Hausen Harald Zur
Villiers Ethel-Michele De
Karin Gunst
Mathis Funk
Perez Iranzu Lamperto
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK3447149T3 publication Critical patent/DK3447149T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK18192671.8T 2013-10-30 2014-10-30 Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer DK3447149T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130005138 EP2868751A1 (en) 2013-10-30 2013-10-30 HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
EP14806534.5A EP3063298B1 (en) 2013-10-30 2014-10-30 Hcbi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for cancer treatment and prevention

Publications (1)

Publication Number Publication Date
DK3447149T3 true DK3447149T3 (da) 2021-05-17

Family

ID=49518640

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14806534.5T DK3063298T3 (da) 2013-10-30 2014-10-30 Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer
DK18192671.8T DK3447149T3 (da) 2013-10-30 2014-10-30 Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14806534.5T DK3063298T3 (da) 2013-10-30 2014-10-30 Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer

Country Status (8)

Country Link
US (1) US10287335B2 (da)
EP (3) EP2868751A1 (da)
JP (1) JP2017500883A (da)
AU (1) AU2014344236B2 (da)
CA (2) CA2922872C (da)
DK (2) DK3063298T3 (da)
ES (2) ES2700746T3 (da)
WO (1) WO2015062726A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2868751A1 (en) * 2013-10-30 2015-05-06 Deutsches Krebsforschungszentrum HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
US20200002723A1 (en) 2014-07-10 2020-01-02 Deutsches Krebsforschungszentrum Msbi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for the treatment and prevention of these diseases
EP3306316A1 (en) * 2016-10-10 2018-04-11 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Rep protein as protein antigen for use in diagnostic assays
EP3517960A1 (en) 2018-01-30 2019-07-31 Deutsches Krebsforschungszentrum Use of bmmf rep protein as biomarker for colon cancer
EP3686289A1 (en) * 2019-01-24 2020-07-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cmi sequences as an early marker for the future development of cancer, atherosclerosis, diabetes and diseases of the cns and as a target for the treatment and prevention of these diseases
EP3699595A1 (en) 2019-02-22 2020-08-26 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as a biomarker for breast cancer
EP3699594A1 (en) 2019-02-22 2020-08-26 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as a biomarker for prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6498242B1 (en) * 1999-02-19 2002-12-24 E. I. Du Pont De Nemours And Company Biological method for the production of adipic acid and intermediates
US20130267429A1 (en) * 2009-12-21 2013-10-10 Lawrence Livermore National Security, Llc Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes
EP2868751A1 (en) * 2013-10-30 2015-05-06 Deutsches Krebsforschungszentrum HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention

Also Published As

Publication number Publication date
CA3065670A1 (en) 2015-05-07
EP3447149A1 (en) 2019-02-27
EP3063298A2 (en) 2016-09-07
CA2922872C (en) 2020-03-10
EP2868751A1 (en) 2015-05-06
WO2015062726A2 (en) 2015-05-07
US10287335B2 (en) 2019-05-14
CA2922872A1 (en) 2015-05-07
ES2867553T3 (es) 2021-10-20
DK3063298T3 (da) 2019-01-07
WO2015062726A3 (en) 2015-06-25
JP2017500883A (ja) 2017-01-12
ES2700746T3 (es) 2019-02-19
AU2014344236B2 (en) 2017-11-23
EP3063298B1 (en) 2018-09-12
US20160244492A1 (en) 2016-08-25
EP3447149B1 (en) 2021-02-17
AU2014344236A1 (en) 2016-03-17
CA3065670C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
EP3691705C0 (en) URINARY CATHETER
IL255261A0 (en) Methods for treating cancer
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
PL3076967T3 (pl) Metody leczenia objawów rezydualnych schizofrenii
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK3738640T3 (da) Krumt urinkateter
DK2970205T3 (da) JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3014157T3 (da) Fleksibelt rør og tilhørende fremgangsmåde
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
EP3259009C0 (en) Improved urinary catheter
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
IL261047A (en) Taf1 inhibitors for the therapy of cancer
DK2903967T3 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og yderligere sygdomme
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
HUE038541T2 (hu) Rák kezelési módszerek
DK3167078T3 (da) HCBI-, MSBI-, MSSI- og CMI-sekvenser til en tidlig markør for fremtidig udvikling af cancer og sygdomme i CNS og som et target for behandling og forebyggelse af disse sygdomme
DK3447149T3 (da) Hcbi-sekvenser som en tidlig markør for fremtidig udvikling af cancer og sygdomme i cns og som et mål for behandling og forebyggelse af cancer
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
LT3563837T (lt) Terapija bakteriofagu
DK3139963T3 (da) Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
DK3071563T3 (da) Midler mod cancer og fremstilling deraf
DK2968377T3 (da) Sammensætninger og fremgangsmåder til behandling af en infektionssygdom